Skip to main content

Table 2 Human chorionic gonadotropin levels (mIU/ml) in patients not treated with MTX (Group 1), treated with MTX by intramuscular injection (Group 2) or treated with MTX by intravenous injection (Group 3)

From: Management of Caesarean scar pregnancy with or without methotrexate before curettage: human chorionic gonadotropin trends and patient outcomes

 

Mean ± SD/Rate

P value

Group 1(n = 47)

Group 2(n = 46)

Group 3(n = 14)

 

A:Before MTX treatment

44,603.28 ± 38,615.27

25,648.86 ± 16,125.92

0.080

B:After MTX treatment or before curettage

31,163.48 ± 28,626.86

37,712.91 ± 23,880.85

31,005.21 ± 23,029.37

0.196

C:Three days after curettage

2838.68 ± 3.10

4434.98 ± 4.90

3263.46 ± 2.93

0.077

B-A

9664.21 ± 8993.10

22,506.29 ± 36,916.63

0.219

(B-A)/A

0.27 ± 0.213

1.33 ± 3.451

0.273

C/B

0.085 ± 0.04

0.084 ± 0.05

0.79 ± 0.04

0.674